MIIP, a cytoskeleton regulator that blocks cell migration and invasion, delays mitosis, and suppresses tumorogenesis

Current Protein and Peptide Science

Volumn 12, Issue 1, 2011, Pages 68-73

  Wang, Yingmei ^a,b   Wen, Jing ^a,c   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cell motility; MIIP; Mitosis; Tumor suppressor gene

Indexed keywords

ALPHA TUBULIN; ALPHA1BETA8 INTEGRIN; COMPLEMENTARY DNA; CORTACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOSKELETON PROTEIN; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 6; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MIGRATION AND INVASION INHIBITORY PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CDC42; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; UNCLASSIFIED DRUG;

CANCER CELL; CANCER INVASION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CYTOSKELETON; DNA MICROARRAY; FOCAL ADHESION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; MICROTUBULE; MITOSIS; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 79958166231     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920311795659434     Document Type: Review

References (50)

1. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
2. Song, S.W.; Fuller, G.N.; Khan, A.; Kong, S.; Shen, W.; Taylor, E.; Ramdas, L.; Lang, F.F.; Zhang, W. IIp45, an insulin-like growth factor binding protein 2 (IGFBP-2) binding protein, antagonizes IGFBP-2 stimulation of glioma cell invasion. Proc. Natl. Acad. Sci. USA, 2003, 100, 13970-13975.
3. Varma, G.; Varma, R.; Huang, H.; Pryshchepava, A.; Groth, J.; Fleming, D.; Nowak, N.J.; McQuaid, D.; Conroy, J.; Mahoney, M.; Moysich, K.; Falkner, K.L.; Geradts, J. Array comparative genomic hybridisation (aCGH) analysis of premenopausal breast cancers from a nuclear fallout area and matched cases from Western New York. Br. J. Cancer, 2005, 93, 699-708.
4. Fujita, T.; Igarashi, J.; Okawa, E.R.; Gotoh, T.; Manne, J.; Kolla, V.; Kim, J.; Zhao, H.; Pawel, B.R.; London, W.B.; Maris, J.M.; White, P.S.; Brodeur, G.M. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst., 2008, 100, 940-949.
5. Gibbs, M.; Stanford, J.L.; McIndoe, R.A.; Jarvik, G.P.; Kolb, S.; Goode, E.L.; Chakrabarti, L.; Schuster, E.F.; Buckley, V.A.; Miller, E.L.; Brandzel, S.; Li, S.; Hood, L.; Ostrander, E.A. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am. J. Hum. Genet., 1999, 64, 776-787.
6. Janoueix-Lerosey, I.; Novikov, E.; Monteiro, M.; Gruel, N.; Schleiermacher, G.; Loriod, B.; Nguyen, C.; Delattre, O. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene, 2004, 23, 5912-5922.
7. Ji, P.; Smith, S.M.; Wang, Y.; Jiang, R.; Song, S.W.; Li, B.; Sawaya, R.; Bruner, J.M.; Kuang, J.; Yu, H.; Fuller, G.N.; Zhang, W. Inhibition of gliomagenesis and attenuation of mitotic transition by MIIP. Oncogene, 2010, 29, 3501-3508.
8. Wang, H.; Shen, W.; Huang, H.; Hu, L.; Ramdas, L.; Zhou, Y.H.; Liao, W.S.; Fuller, G.N.; Zhang, W. Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes. Cancer Res., 2003, 63, 4315-4321.
9. Lee, E.J.; Mircean, C.; Shmulevich, I.; Wang, H.; Liu, J.; Niemisto, A.; Kavanagh, J.J.; Lee, J.H.; Zhang, W. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol. Cancer, 2005, 4, 7.
10. Song, S.W.; Fuller, G.N.; Zheng, H.; Zhang, W. Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. Cancer Res., 2005, 65, 3562-3567.
11. Smith, J.S.; Alderete, B.; Minn, Y.; Borell, T.J.; Perry, A.; Mohapatra, G.; Hosek, S.M.; Kimmel, D.; O'Fallon, J.; Yates, A.; Feuerstein, B.G.; Burger, P.C.; Scheithauer, B.W.; Jenkins, R.B. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene, 1999, 18, 4144-4152.
12. Smith, J.S.; Perry, A.; Borell, T.J.; Lee, H.K.; O'Fallon, J.; Hosek, S.M.; Kimmel, D.; Yates, A.; Burger, P.C.; Scheithauer, B.W.; Jenkins, R.B. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J. Clin. Oncol., 2000, 18, 636-645.
13. Ragnarsson, G.; Eiriksdottir, G.; Johannsdottir, J.T.; Jonasson, J.G.; Egilsson, V.; Ingvarsson, S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer, 1999, 79, 1468-1474.
14. Kaghad, M.; Bonnet, H.; Yang, A.; Creancier, L.; Biscan, J.C.; Valent, A.; Minty, A.; Chalon, P.; Lelias, J.M.; Dumont, X.; Ferrara, P.; McKeon, F.; Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 1997, 90, 809-819.
15. Wang, Y.; Yang, D.; Cogdell, D.; Hu, L.; Xue, F.; Broaddus, R.; Zhang, W. Genomic characterization of gene copy-number aberrations in endometrial carcinoma cell lines derived from endometrioid-type endometrial adenocarcinoma. Technol. Cancer Res. Treat., 2010, 9, 179-189.
16. Cairns, P.; Evron, E.; Okami, K.; Halachmi, N.; Esteller, M.; Herman, J.G.; Bose, S.; Wang, S.I.; Parsons, R.; Sidransky, D. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 1998, 16, 3215-3218.
17. Nomoto, S.; Haruki, N.; Kondo, M.; Konishi, H.; Takahashi, T. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res., 1998, 58, 1380-1383.
18. Imyanitov, E. N. Gene polymorphisms, apoptotic capacity and cancer risk. Hum. Genet., 2009, 125, 239-246.
19. Pilato, B.; Martinucci, M.; Danza, K.; Pinto, R.; Petriella, D.; Lacalamita, R.; Bruno, M.; Lambo, R.; D'Amico, C.; Paradiso, A.; Tommasi, S. Mutations and polymorphic BRCA variants transmission in breast cancer familial members. Breast Cancer Res. Treat., 2010, [Epub ahead of Print].
20. Song, F.; Ji, P.; Zheng, H.; Song, F.; Wang, Y.; Hao, X.; Wei, Q.; Zhang, W.; Chen, K. Definition of a functional single nucleotide polymorphism in the cell migration inhibitory gene MIIP that affects the risk of breast cancer. Cancer Res., 2010, 70, 1024-1032.
21. Fuller, G.N.; Rhee, C.H.; Hess, K.R.; Caskey, L.S.; Wang, R.; Bruner, J.M.; Yung, W.K.; Zhang, W. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res., 1999, 59, 4228-4232.
22. Shariat, S.F.; Lamb, D.J.; Kattan, M.W.; Nguyen, C.; Kim, J.; Beck, J.; Wheeler, T.M.; Slawin, K.M. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and-3 with prostate cancer invasion, progression, and metastasis. J. Clin. Oncol., 2002, 20, 833-841.
23. Wang, H.; Rosen, D.G.; Fuller, G.N.; Zhang, W.; Liu, J. Insulinlike growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod. Pathol., 2006, 19, 1149-1156.
24. Wang, H.; Arun, B.K.; Fuller, G.N.; Zhang, W.; Middleton, L.P.; Sahin, A.A. IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas. Breast J., 2008, 14, 261-267.
25. Renehan, A.G.; Jones, J.; Potten, C.S.; Shalet, S.M.; O'Dwyer, S.T. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br. J. Cancer, 2000, 83, 1344-1350.
26. Wang, G.K.; Hu, L.; Fuller, G.N.; Zhang, W. An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility. J. Biol. Chem., 2006, 281, 14085-14091.
27. Schutt, B.S.; Langkamp, M.; Rauschnabel, U.; Ranke, M.B.; Elmlinger, M.W. Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J. Mol. Endocrinol., 2004, 32, 859-868.
28. Wu, Y.; Song, S.W.; Sun, J.; Bruner, J.M.; Fuller, G.N.; Zhang, W. IIp45 inhibits cell migration through inhibition of HDAC6. J. Biol. Chem., 2010, 285, 3554-3560.
29. Valenzuela-Fernandez, A.; Cabrero, J.R.; Serrador, J.M.; Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol., 2008, 18, 291-297.
30. Zhang, Y.; Gilquin, B.; Khochbin, S.; Matthias, P. Two catalytic domains are required for protein deacetylation. J. Biol. Chem., 2006, 281, 2401-2404.
31. Yoshida, N.; Omoto, Y.; Inoue, A.; Eguchi, H.; Kobayashi, Y.; Kurosumi, M.; Saji, S.; Suemasu, K.; Okazaki, T.; Nakachi, K.; Fujita, T.; Hayashi, S. Prediction of prognosis of estrogen receptorpositive breast cancer with combination of selected estrogenregulated genes. Cancer Sci., 2004, 95, 496-502.
32. Sakuma, T.; Uzawa, K.; Onda, T.; Shiiba, M.; Yokoe, H.; Shibahara, T.; Tanzawa, H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int. J. Oncol., 2006, 29, 117-124.
33. Bazzaro, M.; Lin, Z.; Santillan, A.; Lee, M.K.; Wang, M.C.; Chan, K.C.; Bristow, R.E.; Mazitschek, R.; Bradner, J.; Roden, R.B. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin. Cancer Res., 2008, 14, 7340-7347.
34. Gloghini, A.; Buglio, D.; Khaskhely, N.M.; Georgakis, G.; Orlowski, R.Z.; Neelapu, S.S.; Carbone, A.; Younes, A. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br. J. Haematol., 2009, 147, 515-525.
35. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417, 455-458.
36. Zhang, X.; Yuan, Z.; Zhang, Y.; Yong, S.; Salas-Burgos, A.; Koomen, J.; Olashaw, N.; Parsons, J.T.; Yang, X.J.; Dent, S.R.; Yao, T.P.; Lane, W.S.; Seto, E. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol. Cell, 2007, 27, 197-213.
37. Aoyagi, S.; Archer, T.K. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends. Cell Biol., 2005, 15, 565-567.
38. Tran, A.D.; Marmo, T.P.; Salam, A.A.; Che, S.; Finkelstein, E.; Kabarriti, R.; Xenias, H.S.; Mazitschek, R.; Hubbert, C.; Kawaguchi, Y.; Sheetz, M.P.; Yao, T.P.; Bulinski, J.C. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J. Cell Sci., 2007, 120, 1469-1479.
39. Tsutsumi, S.; Beebe, K.; Neckers, L. Impact of heat-shock protein 90 on cancer metastasis. Future Oncol., 2009, 5, 679-688.
40. Koga, F.; Tsutsumi, S.; Neckers, L.M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle, 2007, 6, 1393-1402.
41. Masson-Gadais, B.; Houle, F.; Laferriere, J.; Huot, J. Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperones, 2003, 8, 37-52.
42. Rousseau, S.; Houle, F.; Kotanides, H.; Witte, L.; Waltenberger, J.; Landry, J.; Huot, J. Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J. Biol. Chem., 2000, 275, 10661-10672.
43. Yu, H. Cdc20: a WD40 activator for a cell cycle degradation machine. Mol. Cell, 2007, 27, 3-16.
44. Matsuyama, A.; Shimazu, T.; Sumida, Y.; Saito, A.; Yoshimatsu, Y.; Seigneurin-Berny, D.; Osada, H.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Horinouchi, S.; Yoshida, M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J., 2002, 21, 6820-6831.
45. Westermann, S.; Weber, K. Post-translational modifications regulate microtubule function. Nat. Rev. Mol. Cell Biol., 2003, 4, 938-947.
46. Reed, N.A.; Cai, D.; Blasius, T.L.; Jih, G.T.; Meyhofer, E.; Gaertig, J.; Verhey, K.J. Microtubule acetylation promotes kinesin-1 binding and transport. Curr. Biol., 2006, 16, 2166-2172.
47. Dompierre, J.P.; Godin, J.D.; Charrin, B.C.; Cordelieres, F.P.; King, S.J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci., 2007, 27, 3571-3583.
48. Sudo, H.; Maru, Y. LAPSER1 is a putative cytokinetic tumor suppressor that shows the same centrosome and midbody subcellular localization pattern as p80 katanin. FASEB J., 2007, 21, 2086-2100.
49. Privette, L.M.; Weier, J.F.; Nguyen, H.N.; Yu, X.; Petty, E.M. Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia, 2008, 10, 643-652.
50. Wickstrom, S.A.; Masoumi, K.C.; Khochbin, S.; Fassler, R.; Massoumi, R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J., 2010, 29, 131-144.